|
|
We’ve been hearing it constantly: the COVID-19 vaccine is safe, effective, and free…so how could you NOT roll up your sleeve?
But despite the claim by politicians, the vaccine is not free. The governments take taxpayer money and give it to the drug dealers who have already reaped great profits.
The U.S., in fact, just cut a check to buy 200 million additional COVID-19 doses from Pfizer for a cool $24 a jab, The Wall Street Journal reported. That’s a noticeable increase from $19.50 for the earlier batch.
The paper reported that the number brings the total number of doses for the U.S. to about a billion—more than triple its population of 328 million. (Booster shot anyone?)
The doses are expected to be delivered in two shipments—about 110 million by the end of the year—and the rest by next April. The Trends Journal has predicted new lockdowns by the fall due to the Delta variant, so…perfect timing. Under the agreement, the U.S. will be able to purchase vaccines that focus on variants.
The paper pointed out that Jen Psaki, the White House press secretary, said these doses could be earmarked for booster shots and for use among children… despite few children dying from the virus and having a 99.997 percent recovery rate according to the Centers for Disease Control and Prevention.
“The price for this order accounts for the additional investment necessary to produce, package, and deliver new formulations of the vaccine, as well as the increased cost associated with delivering the vaccine and smaller pack sizes to facilitate delivery at individual provider offices, including pediatricians,” Pfizer said in a statement obtained by the Journal.
TRENDPOST: On 11 May, the Trends Journal published an article, “DRUG COMPANIES CASHING IN ON COVID,” and we pointed out a press release from Pfizer that was encouraged about a new “durable” revenue stream in the wake of the outbreak.
“The drugmaker reported a jump in first-quarter profits based on surging revenues, with nearly one-fourth of sales coming from Covid-19 vaccines. With German partner BioNTech, the pharma giant is ramping up vaccine production and now estimates 2021 revenues of $26 billion from the vaccine, up from the $15 billion projected in February,” the statement said.
(See our 13 April article, “MEDIA: GET JABBED, END THE COVID WAR,” our 24 March 2020 article, “CORONAVIRUS: POLITICAL LEADERS ON THE WARPATH,” and our 21 July 2020 article, “COVID WAR: FEAR SELLS COVID WAR: FEAR SELLS.”)
Albert Bourla, the Pfizer CEO, told analysts on a conference call in May that he expects a “durable demand” for the vaccines and compared it to the flu vaccine.
The company is building more capacity and expects to manufacture at least three billion doses in 2022, up from 2.5 billion now expected in 2021, the statement read.